Nasdaq zyne.

Zynerba Pharmaceuticals Inc stock price live 1.300, this page displays NASDAQ ZYNE stock exchange data. View the ZYNE premarket stock price ahead of the market session …DEVON, Pa., July 19, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced that it intends to offer and sell, subject to market conditions, shares of its common ...15 de ago. de 2023 ... Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock is up some 300%. ZYNE stock is up because Harmony is offering to buy the whole company.Meeting to Reconvene on July 27, 2023 at 9:00 am EDT. DEVON, Pa., June 28, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative ...

Direct. 23,109. $0.00. 28,109. Back to ZYNE Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC ... Zynerba Pharmaceuticals Inc stock price live 1.300, this page displays NASDAQ ZYNE stock exchange data. View the ZYNE premarket stock price ahead of the market session or assess the after hours quote.The Zynerba Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

ZYNE investors should be aware of a decrease in hedge fund interest recently. Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) was in 7 hedge funds' portfolios at the end of September. The all time high ...PLYMOUTH MEETING, Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), today announced that Xylophone Acquisition Corp., a wholly owned subsidiary of Harmony, has extended the expiration of its tender offer to acquire all of the outstanding shares of common stock of Zynerba ...

American Resources Corporation (NASDAQ: AREC) was in 3 hedge funds' portfolios at the end of March. The all time high for this statistic is 1. This means the bullish number of hedge fund positions ...Dec 4, 2023 · How much profit does Zynerba Pharmaceuticals generate each year? Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a recorded net income of -$35.04 million. ZYNE has generated -$0.80 earnings per share over the last four quarters. Luis Sanay, CFA. 445-235-8386. [email protected]. Harmony Biosciences Media Contact: Cate McCanless. 202-641-6086. [email protected]. SOURCE Harmony Biosciences ...DEVON, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...

Find the latest stock market trends and activity today. Compare key indexes, including Nasdaq Composite, Nasdaq-100, Dow Jones Industrial & more.

27 Sep, 2023, 08:00 ET. PLYMOUTH MEETING, Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq ...

Oct 11, 2023 · Healthcare company Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) completed its previously announced acquisition of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) on Wednesday.. What Happened ... Jan 11, 2023 · Find the latest Earnings Report Date for Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) at Nasdaq.com. Links ZYNE StockTwits. Show Market Indexes. No Data. *** StockConsultant data not available for this stock. Consulting data available on NASDAQ, NYSE, and AMEX ...PLYMOUTH MEETING, Pa. and DEVON, Pa., Aug. 14, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ("Zynerba") (Nasdaq: ZYNE), a leader in ...PLYMOUTH MEETING, Pa. and DEVON, Pa., Aug. 14, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ("Zynerba") (Nasdaq: ZYNE), a leader in ...15 de ago. de 2023 ... Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock is up some 300%. ZYNE stock is up because Harmony is offering to buy the whole company.Zynerba Pharmaceuticals (NASDAQ:ZYNE) US$4.97 / Market Cap: US$102.82 million / Year-to-date: +33.6 percent increase This pharmaceutical company is focused on the development of synthetic ...

Links ZYNE StockTwits. Show Market Indexes. No Data. *** StockConsultant data not available for this stock. Consulting data available on NASDAQ, NYSE, and AMEX ...14 de ago. de 2023 ... ("Zynerba") (Nasdaq: ZYNE), a leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric ...DEVON, Pa., April 10, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and ...Plymouth Meeting, PA, and Devon, Pa, August 14, 2023 — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba …May 5, 2021 · DEVON, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ... The Drop-Offs. The companies that fell from GMR's Cannabis Index are: Aphria Inc (NASDAQ:APHA), which Tilray Inc. (NASDAQ:TLRY) acquired in May.. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), which ...

Sep 27, 2023 · PLYMOUTH MEETING, Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), today announced that Xylophone Acquisition Corp., a wholly owned subsidiary of Harmony, has extended the expiration of its tender offer to acquire all of the outstanding shares of common stock of Zynerba ...

DEVON, Pa., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...Nov 25, 2023 · What is Zynerba Pharmaceuticals' stock price target for 2024? 4 analysts have issued twelve-month price objectives for Zynerba Pharmaceuticals' shares. Their ZYNE share price targets range from $1.11 to $1.11. On average, they predict the company's share price to reach $1.11 in the next year. DEVON, Pa., March 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and ...DEVON, Pa., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...Nasdaq Futures 14,472.00 -18.25(-0.13%) Russell 2000 Futures 1,664.50 -3.90(-0.23%) Crude Oil 81.14 +0.12(+0.15%) Gold 1,986.00 -8.30(-0.42%) Zynerba Pharmaceuticals, …DEVON, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...119,741. 10,303. 9.414%. $137. Back to ZYNE Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions ...

DEVON, Pa., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...

Meeting to Reconvene on July 27, 2023 at 9:00 am EDT. DEVON, Pa., June 28, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative ...

DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...Nasdaq Futures 14,472.00 -18.25(-0.13%) Russell 2000 Futures 1,664.50 -3.90(-0.23%) Crude Oil 81.14 +0.12(+0.15%) Gold 1,986.00 -8.30(-0.42%) Zynerba Pharmaceuticals, …Zynerba Pharmaceuticals (NASDAQ:ZYNE), a drug developer focused on rare neuropsychiatric disorders, added ~276% in the morning hours Monday after Harmony Biosciences (NASDAQ:HRMY) agreed to ...DEVON, Pa., April 12, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic ...Oct 11, 2023 · New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion syndrome PLYMOUTH MEETING, PA, October 11, 2023 — Harmony Biosciences ... Back to ZYNE Overview. Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is ...Under the terms of the deal, Harmony will pay shareholders of Devon-based Zynerba (NASDAQ: ZYNE) $1.1059 per share in cash plus one non-tradable contingent value right per share. The latter ...(RTTNews) - Zynerba Pharmaceuticals Inc. (ZYNE), in an update on its meeting with the U.S. Food and Drug Administration regarding its Fragile X syndrome or FXS program, said that it plans to ...Dec 4 (Reuters) - Wall Street was set to open lower on Monday, as investors turned wary ahead of a slew of economic data this week that is likely to test the narrative …

PLYMOUTH MEETING, Pa., Oct. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company …DEVON, Pa., Feb. 25, 2016 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), please note that in the second paragraph of ...DEVON, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...Feb 11, 2021 · MSFT. Microsoft Corporation Common Stock. $242.05 +0.83 0.34%. Find the latest news headlines from Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) at Nasdaq.com. Instagram:https://instagram. cows etfhow many mortgages can i haveaapl.earnings dateelon musk electric Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE) Under the terms of the Agreement, Zynerba will be acquired by Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq - HRMY). Harmony will ... top 20 annuity companiesshipping company stocks MSFT. Microsoft Corporation Common Stock. $242.05 +0.83 0.34%. Find the latest news headlines from Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) at Nasdaq.com. jobs marten transport Shares of Zynerba Pharmaceuticals Inc. ZYNE, +0.89% jumped 300% premarket on Monday after Harmony Biosciences Holdings Inc. HRMY, -0.47% said it would acquire the cannabinoid therapy company in a deal...DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...